SCHEMBL250459

SCHEMBL250459

O=C(O)CNC1CCCCCCCCCCC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
DPP7 Q9UHL4 5/20 0.47
KDM4E B2RXH2 3/20 0.46
EPHX1 P07099 5/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.46
CYP3A4 P08684 1/20 0.46
EPHX2 P34913 1/20 0.46
DPP4 P27487 7/20 0.46
FAP Q12884 4/20 0.46
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL173401 1.00 ALDH1A1 (0.50) ALDH1A1DPP7KDM4EEPHX1NPC1
SCHEMBL201078 1.00 ALDH1A1 (0.50) ALDH1A1DPP7KDM4EEPHX1NPC1
SCHEMBL28833359 1.00 ALDH1A1 (0.50) ALDH1A1DPP7KDM4EEPHX1NPC1
SCHEMBL163395 1.00 ALDH1A1 (0.50) ALDH1A1DPP7KDM4EEPHX1NPC1
SCHEMBL122347 1.00 ALDH1A1 (0.50) ALDH1A1DPP7KDM4EEPHX1NPC1
SCHEMBL159315 1.00 ALDH1A1 (0.50) ALDH1A1DPP7KDM4EEPHX1NPC1
SCHEMBL17338009 0.98 ALDH1A1 (0.48) ALDH1A1DPP7KDM4EEPHX1NPC1
SCHEMBL15268412 0.98 ALDH1A1 (0.48) ALDH1A1DPP7KDM4EEPHX1NPC1
SCHEMBL17338024 0.98 ALDH1A1 (0.48) ALDH1A1DPP7KDM4EEPHX1NPC1
SCHEMBL22029349 0.98 ALDH1A1 (0.48) ALDH1A1DPP7KDM4EEPHX1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 882 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1621546-B1 Peptide ligands specific to immonoglobulins TECNOGEN SPA (IT) 2008-10-29 EP claimed
EP-1621546-A1 Peptide ligands specific to immonoglobulins TECNOGEN S.C.P.A. (IT) 2006-02-01 EP claimed
US-20260140060-A1 COLORIMETRIC DETECTION OF A VIRAL INFECTION RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2026-05-21 US disclosed
US-20260124281-A1 FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE ENTERA BIO LTD. (IL) 2026-05-07 US disclosed
US-20260109870-A1 PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2026-04-23 US disclosed
US-12576191-B2 Method of inducing cardiomyocytes proliferation and treating heart diseases YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2026-03-17 US disclosed
US-20260069728-A1 MULTI-TARGETING COMPOUND AND USE THEREOF CHENGDU SHETAI MEDICAL TECHNOLOGY CO., LTD. (CN) 2026-03-12 US disclosed
EP-3980085-B1 COMPOSITIONS AND METHODS OF USING SAME FOR TISSUE REGENERATION UNIV RAMOT (IL) 2026-03-11 EP disclosed
EP-3606615-B1 METHOD OF STRAIGHTENING HAIR, METHOD FOR MAINTENANCE OF STRAIGHTENED HAIR AND KIT FOR STRAIGHTENING HAIR YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) 2026-01-07 EP disclosed
US-20250369136-A1 PEPTIDE SELF-ASSEMBLY AS A STRATEGY FOR FACILE IMMOBILIZATION OF ENZYMES AND MICROORGANISMS ON ELECTRODES RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2025-12-04 US disclosed
US-20250319054-A1 Synthetic Eicosanoid Analogues for the Treatment and Prevention of Diseases Associated with Increased GDF15 Plasma Concentration OMEICOS THERAPEUTICS GMBH (DE) 2025-10-16 US disclosed
WO-1997005257-A1 PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1997-02-13 WO disclosed
EP-0745092-A1 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1996-12-04 EP disclosed
US-5480871-A TREATMENT OF BENIGN PROSTATIC HYPERPLASIA CHIRON CORPORATION (US) 1996-01-02 US disclosed
WO-1995027729-A1 OPIATE RECEPTOR LIGANDS CHIRON CORPORATION (US) 1995-10-19 WO disclosed
EP-0672049-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1995-09-20 EP disclosed
WO-1995004072-A1 PEPTOID ALPHA-1 ADRENERGIC RECEPTOR LIGANDS CHIRON CORPORATION (US) 1995-02-09 WO disclosed
WO-1994028014-A2 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1994-12-08 WO disclosed
WO-1994011388-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1994-05-26 WO disclosed
WO-1994003483-A1 ENDOTHELIN RECEPTOR-BINDING COMPOUNDS CHIRON CORPORATION (US) 1994-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250319054-A1 Synthetic Eicosanoid Analogues for the Treatment and Prevention of Diseases Associated with Increased GDF15 Plasma Concentration IL15, ALOX15, FABP3 ALDH1A1 3149/4885DPP7 1311/4885KDM4E 4698/4885
US-20260124281-A1 FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE PTH1R, FGF23, PTMS ALDH1A1 2763/4885DPP7 2428/4885KDM4E 2999/4885
US-20260109870-A1 PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME NONO, NGLY1, PTMS ALDH1A1 4370/4885DPP7 537/4885KDM4E 1513/4885
US-20260069728-A1 MULTI-TARGETING COMPOUND AND USE THEREOF CXCR4, CXCR2, GRPR ALDH1A1 1068/4885DPP7 657/4885KDM4E 4703/4885
US-12576191-B2 Method of inducing cardiomyocytes proliferation and treating heart diseases MYLK2, TNNI3, MYL6 ALDH1A1 4773/4885DPP7 2547/4885KDM4E 1990/4885
US-20260140060-A1 COLORIMETRIC DETECTION OF A VIRAL INFECTION CTSL, CPA4, ACE2 ALDH1A1 1754/4885DPP7 86/4885KDM4E 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.